Monday, October 04, 2021 7:20:54 AM
Merck pill is a therapeutic. Pfizer product is a vaccine.
New York Yankees and Duke Basketball
Recent MRK News
- Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration • Business Wire • 04/02/2026 10:50:00 AM
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens • Business Wire • 04/02/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:47:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:44:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:42:51 PM
- Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 • Business Wire • 04/01/2026 11:00:00 AM
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins • Business Wire • 03/30/2026 03:45:00 PM
- Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction • Business Wire • 03/29/2026 03:45:00 PM
- Enliven Therapeutics shares jump 28% after Merck’s $6.7 billion Terns acquisition announcement • IH Market News • 03/25/2026 02:05:57 PM
- Terns Pharma stock jumps on report of potential $6B takeover by Merck • IH Market News • 03/25/2026 10:52:24 AM
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) • GlobeNewswire Inc. • 03/25/2026 10:48:00 AM
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) • Business Wire • 03/25/2026 10:45:00 AM
- New Public Listings for Canadians Living with Pulmonary Arterial Hypertension • PR Newswire (Canada) • 03/24/2026 11:30:00 AM
- Nouvelles inscriptions de produits à la liste de médicaments provinciale destinées aux Canadiens atteints d'hypertension artérielle pulmonaire • PR Newswire (Canada) • 03/24/2026 11:30:00 AM
- FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs • Business Wire • 03/18/2026 08:30:00 PM
- Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026 • Business Wire • 03/17/2026 10:50:00 AM
- Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research • Business Wire • 03/16/2026 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 05:52:51 PM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (Canada) • 03/03/2026 02:00:00 PM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (US) • 03/03/2026 02:00:00 PM
- KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC) • Business Wire • 02/28/2026 03:05:00 PM
- WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) • Business Wire • 02/28/2026 03:00:00 PM
- KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer • Business Wire • 02/27/2026 03:15:00 PM
- KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery • Business Wire • 02/27/2026 03:00:00 PM
- FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis • Business Wire • 02/25/2026 09:30:00 PM
